• Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan

    10 days ago - By San Diego Biotechnology

    TOKYO & SAN DIEGO--Kyowa Kirin Co., Ltd. , a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology and MEI Pharma, Inc. , a late-stage pharmaceutical company...
    Read more ...